Medpace Holdings, Inc. - Common Stock (MEDP)

Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expecta...

Medpace’s third quarter saw steady growth, with management attributing performance to robust demand for clinical research services and a healthy pipeline of ...

Cancellations now stem from clinical failures rather than funding shortages, signaling a healthier market for contract research.

Record net new business awards and 23.7% net income growth signal strong momentum.

Clinical research company Medpace Holdings (NASDAQ:MEDP) met Wall Street’s revenue expectations in Q3 2026, with sales up 8.5% year on year to $716 million. ...

Medpace (NASDAQ:MEDP) reported third-quarter 2026 revenue growth of 8.5% and record net new business awards, while management said the clinical research organization continues to see a strong operating environment marked by healthy request-for-proposal activity, initial award notifications and win r

Clinical research company Medpace Holdings (NASDAQ:MEDP) met Wall Street’s revenue expectations in Q3 2026, with sales up 8.5% year on year to $716 million. ...

Clinical research company Medpace Holdings (NASDAQ:MEDP) will be announcing earnings results this Wednesday after the bell. Here’s what you need to know. Med...

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorab...

Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three ...

Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability ...

Medpace Holdings (NASDAQ:MEDP) has outperformed the market over the past 5 years by 15.31% on an annualized basis producing an average annual return of 26.82%. Currently, Medpace Holdings has a market capitalization of

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only reali...

Medpace currently trades at $610.21 and has been a dream stock for shareholders. It’s returned 238% since August 2021, more than tripling the S&P 500’s 70.1%...

Medpace Holdings (NASDAQ:MEDP) has outperformed the market over the past 10 years by 22.9% on an annualized basis producing an average annual return of 36.28%. Currently, Medpace Holdings has a market capitalization of

Troendle retains a $3.27 billion combined stake, representing 19% of the market cap, with the majority of holdings controlled through Medpace Investors, LLC.

Medpace Holdings (NASDAQ:MEDP) has outperformed the market over the past 5 years by 14.56% on an annualized basis producing an average annual return of 26.38%. Currently, Medpace Holdings has a market capitalization of

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services ind...

Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to beco...

Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expecta...

Companies with more cash than debt often have stronger financial flexibility, making them attractive in uncertain markets. With interest payments less of a w...

Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such a...

What Happened? Shares of clinical research company Medpace Holdings (NASDAQ:MEDP) jumped 14.4% in the afternoon session after the company reported second-qua...

Medpace (NASDAQ:MEDP) reported double-digit growth in second-quarter revenue and earnings, while management described the business environment as strong and said lower cancellations helped drive record net bookings. CEO August Troendle said on the company’s second-quarter 2026 earnings call that ca